Clinical Utility of Preoperative Thyroid GuidePx® Testing
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Calgary
About this trial
The purpose of this study is to learn whether having Thyroid GuidePx® test results available before treatment may help patients with papillary thyroid cancer and doctors make better-informed treatment decisions.
Eligibility criteria
Qualifiers
Patients aged 18 years or older at the time of enrollment
English-speaking
Bethesda V or VI cytology following FNA of a thyroid nodule (papillary thyroid cancer)
Bethesda III or IV with ThyroSpec positive for BRAFV600E, TERT, rearrangements in BRAF, RET, NTRK1, NTRK3, RAS + TERT, RAS + EIF1AX, AKT1, PI3CA, CTNNB1, EGFR, rearrangements in ALK
Disqualifiers
Prior thyroid operation
Distant metastatic disease
Personal history of thyroid cancer
History of whole-body radiation exposure or radiation to the head and neck region
Trial design
Treatments tested in this trial
- Not listed
Trial groups
85 Participants
are grouped into 1 trial groupLocations
Sponsors and collaborators
University of Calgary
Lead sponsor
Qualisure Diagnostics Inc.
Collaborator
University of Alberta
Collaborator
Source ClinicalTrials.gov